Get the Stockscreener App
6.65
57.96%
2.44
After Hours:
6.50
-0.15
-2.26%
Capricor Therapeutics Inc stock is traded at $6.65, with a volume of 65.82M.
It is up +57.96% in the last 24 hours and down -67.84% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$4.21
Open:
$7.66
24h Volume:
65.82M
Relative Volume:
17.10
Market Cap:
$385.11M
Revenue:
$11.13M
Net Income/Loss:
$-114.59M
P/E Ratio:
-2.8751
EPS:
-2.313
Net Cash Flow:
$-113.96M
1W Performance:
+62.59%
1M Performance:
-67.84%
6M Performance:
-70.38%
1Y Performance:
-14.52%
1-Day Range:
$6.04
$8.15
1-Week Range:
$3.73
$8.15
52-Week Range:
$2.96
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.65 | 242.65M | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - PR Newswire
CAPRICOR THERAPEUTICS, INC. 2026: Revenue $14.08M, EPS ($0.7) — 10-Q Summary - TradingView
Tang Capital group discloses 7.1% Capricor (CAPR) ownership in amended 13G - Stock Titan
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP - The AI Journal
CAPR Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
Capricor Therapeutics (CAPR) Sees Surge Amid Deramiocel Update - GuruFocus
Capricor shares soar as potential FDA lifeline revives Duchenne drug hopes - KWSN
Capricor Therapeutics jumps 75% amid FDA talks on Duchenne Muscular Dystrophy drug update - Pluang
Capricor: Stock Now Surging On Fresh BLA UpdatesWhat Investors Must Know (NASDAQ:CAPR) - Seeking Alpha
12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com
Why is Capricor Therapeutics stock surging today? - Investing.com
Capricor Shares Rise with FDA Review of Latest Duchenne Data, Eyes on August 22 Event - TechStock²
Capricor's DMD therapy deramiocel gets regulatory lifeline, shares surge - FirstWord Pharma
Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data - Endpoints News
Capricor Therapeutics jumps as investors focus on ongoing FDA review and fresh deramiocel update - Quiver Quantitative
Capricor soars on plan to amend DMD filing after adcomm setback - Fierce Biotech
Why Is Capricor Therapeutics Stock Soaring Today?Capricor Therapeutics (NASDAQ:CAPR) - benzinga.com
CAPR Stock In Focus As Lancet Data And Analyst Upgrades Collide - timothysykes.com
Capricor stock upgraded at Cantor on plans for lead drug (CAPR) - Seeking Alpha
This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - benzinga.com
Capricor Therapeutics (CAPR) Stock Surges on FDA Application Amendment Plans - GuruFocus
CAPR Stock Draws Traders As Lancet Data And Big Upgrade Hit - StocksToTrade
12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com
Capricor Therapeutics (CAPR) Rockets 115% Pre-Market Amid Valuation and Insider Activity Spotlight - GuruFocus
CAPRICOR THERAPEUTICS ($CAPR) Releases Q2 2026 Earnings - Moomoo
CAPR Stock Jumps As Lancet Data And Upgrade Shift Odds - StocksToTrade
Why is Capricor Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
Capricor surges on amended plans for lead drug (CAPR:NASDAQ) - Seeking Alpha
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data - BNN Bloomberg
CAPR Upgraded by Cantor Fitzgerald -- Price Target Raised to $28.00 - GuruFocus
CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path - Yahoo Finance
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers - Yahoo Finance
Why Is CAPR Stock Soaring Premarket? This Analyst Sees A New FDA Path For Deramiocel - Stocktwits
$Capricor Therapeutics (CAPR.US)$ Just here to join the fun, let's go up! - Moomoo
Capricor Therapeutics (CAPR) Q2 2026 Earnings Call: Deramocel BLA Path and FDA Update - TradingKey
Cantor Fitzgerald upgrades Capricor stock rating on regulatory progress By Investing.com - Investing.com Canada
Cantor Fitzgerald upgrades Capricor stock rating on regulatory progress - Investing.com
Key facts: Capricor (NASDAQ:CAPR) Q2 loss $40.7M; HOPE-3 breach suit - TradingView
Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why - Benzinga
Capricor Therapeutics Inc (CAPR) (Q2 2026) Earnings Call Highlights: Navigating FDA Setback and Strategic Pivot - GuruFocus
Capricor Therapeutics Inc (CAPR) (Q2 2026) Earnings Call Highlights: Navigating FDA Setback and ... - Yahoo Finance
Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Inves - The National Law Review
Kaplan Fox Announces a Securities Class Action Filed Against Capr - The National Law Review
Kaplan Fox Reminds Investors of Capricor Therapeutics, Inc. (NASD - The National Law Review
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
Capricor Therapeutics Faces Securities Lawsuit - stl.news
Kaplan Fox Continues to Remind Capricor Therapeutics, Inc. (NASDA - The National Law Review
Capricor Outlines Clearer Regulatory Path for Deramiocel - Intellectia AI
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure ... - Caledonian Record
Capricor Therapeutics (CAPR) Faces FDA Setback Ahead of PDUFA Da - GuruFocus
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor - GlobeNewswire
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):